Macarena de la Fuente, MD, is an associate professor of neuro-oncology, chief of the Neuro-Oncology Division, clinical service leader for Neuro-Oncology Service Line - Sylvester Comprehensive Cancer Center, chair of the Neuro-Oncology Site Disease Group, director of the Neuro-Oncology Fellowship Program, and oncology clinical service leader for Neuro-Oncology at the Miller School of Medicine of University of Miami in Florida.

Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma

"This is a study that combined vorasidenib with temozolomide for patients with 

-mutant glioma. It is the first time that we’ve seen this combination [evaluated] in 

mutant tumors. We are excited about the safety profile of the combination and moving it forward to the phase 2 part of the study."

Macarena de la Fuente, MD, an associate professor of neuro-oncology, chief of the Neuro-Oncology Division, clinical service leader for Neuro-Oncology Service Line - Sylvester Comprehensive Cancer Center, chair of the Neuro-Oncology Site Disease Group, director of the Neuro-Oncology Fellowship Program, and oncology clinical service leader for Neuro-Oncology at the Miller School of Medicine of University of Miami in Florida, shared early safety data from the phase 1b IDHEAL-4U trial (NCT05592743), which evaluated the addition of vorasidenib (Voranigo) to temozolomide (Temodar) in patients with glioma harboring 

Vorasidenib is a brain penetrant dual IDH inhibitor that has been approved by the FDA for treating adult and pediatric patients with grade 2 astrocytoma or oligodendroglioma possessing a susceptible 

 mutation following surgery, de la Fuente began. However, standard care for more aggressive, higher-grade gliomas involves radiation with chemotherapy, and prior to this study, no safety or efficacy data existed for this combination, she noted.

IDHEAL-4U is a multicenter phase 1b/2 trial, with the phase 1b portion focusing specifically on safety. Investigators enrolled patients at least 12 years of age with grade 2 to 4 

-mutant gliomas who were eligible for temozolomide in the adjuvant setting or at first recurrence.

Findings presented at the 2025 Society for Neuro-Oncology Annual Meeting showed that combining vorasidenib and temozolomide did not lead to any serious adverse effects (SAEs) or dose-limiting toxicities (DLTs), de la Fuente reported. Although all 7 patients experienced any-grade treatment-emergent adverse effects (TEAEs) over a median duration of 5.5 months, only 28.6% (n = 2) had grade 3 or higher TEAEs, including decreased neutrophil count (14.3%) and decreased platelet count (28.6%). Crucially, no patients discontinued treatment due to TEAEs, and all patients completed the DLT evaluation.

Accordingly, the recommended combinatory dose (RCD) was established as 40 mg of vorasidenib administered daily, combined with a standard dose of temozolomide, de la Fuente shared. This dose combination is currently being evaluated in the phase 2 portion of the study. Researchers expressed excitement over the safety profile, as this is the first time this specific combination has been studied in 

Videos

Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.




Macarena de la Fuente, MD

Articles

Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma